QQ客服 官方微博 反馈留言

浏览/检索结果: 共7条，第1-7条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序提交时间升序提交时间降序题名升序题名降序作者升序作者降序 Effect of autoinduction and food on the pharmacokinetics of furmonertinib and its active metabolite characterized by a population pharmacokinetic model 期刊论文 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10 作者:  Zou, Hui-xi;  Zhang, Yu-feng;  Zhong, Da-fang;  Jiang, Yong;  Liu, Fei 收藏  |  浏览/下载：17/0  |  提交时间：2022/01/04 furmonertinib  autoinduction  food effect  alkaline phosphatase  body weight  pharmacokinetics  modeling and simulation  NSCLC   Furmonertinib (Alflutinib, AST2818) is a potential positive control drug comparable to rifampin for evaluation of CYP3A4 induction in sandwich-cultured primary human hepatocytes 期刊论文 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10 作者:  Wu, Ya-li;  Xue, Ya-ru;  Guo, Zi-tao;  Chen, Zhen-dong;  Ge, Xin-yu 收藏  |  浏览/下载：19/0  |  提交时间：2021/08/17 furmonertinib (alflutinib  AST2818)  quantitative proteomics  sandwich-cultured human hepatocytes   Safety, Clinical Activity, and Pharmacokinetics of Al flutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation 期刊论文 JOURNAL OF THORACIC ONCOLOGY, 2020, 卷号: 15, 期号: 6, 页码: 1015-1026 作者:  Shi, Yuankai;  Zhang, Shucai;  Hu, Xingsheng;  Feng, Jifeng;  Ma, Zhiyong 收藏  |  浏览/下载：36/0  |  提交时间：2020/12/24 Alflutinib  NSCLC  EGFR T790M mutation  Efficacy  Safety   Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer 期刊论文 ACTA PHARMACOLOGICA SINICA, 2020, 页码: 11 作者:  Liu, Xiao-yun;  Guo, Zi-tao;  Chen, Zhen-dong;  Zhang, Yi-fan;  Zhou, Jia-lan 收藏  |  浏览/下载：76/0  |  提交时间：2020/07/01 alflutinib  AST5902  metabolism  enzyme induction  drug-drug interaction   Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry 期刊论文 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2019, 卷号: 176, 页码: 6 作者:  Liu, Xiaoyun;  Li, Wei;  Zhang, Yifan;  Jian, Yong;  Zhao, Qianyu 收藏  |  浏览/下载：14/0  |  提交时间：2020/07/01 LC-MS/MS  Alflutinib  AST2818  Pharmacokinetics  Human plasma   LC-MS/MS法同时测定人血浆中AST2818和去甲基代谢物 会议论文 作者:  刘晓云;  李卫;  张逸凡;  陈笑艳;  钟大放 收藏  |  浏览/下载：60/0  |  提交时间：2019/01/08 LC-MS/MS  AST2818  M1  药代动力学   Third Generation EGFR Inhibitor AST2818 (Alflutinib) in NSCLC Patients with EGFR T790M Mutation: A phase1/2 Multi-Center Clinical Trial 期刊论文 2017, 卷号: 12, 期号: 11, 页码: S2137-S2137 作者:  Shi, Y.;  Hu, X.;  Zhang, S.;  Yang, N.;  Zhang, Y. 收藏  |  浏览/下载：15/0  |  提交时间：2020/01/04 Targeted therapy  Third generation EGFR TKI  EGFR T790M mutant NSCLC